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chemical and chemo-enzymatic tools for the access to 1,2-trans or 1,2-cis linkages. Finally, innovative applications related to bio-
logical, chemical and physicochemical ﬁelds for both natural and synthetic hexofuranosyl compounds will be described.
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Glycoconjugates are known to play important roles in
numerous biological events.1 Most of the time, mono-
saccharide constituents are found in the hexopyranosyl
form. During the last two decades, biomolecules involv-
ing hexofuranosyl constituents have attracted interest
due to (i) their presence in various micro-organisms,
even pathogenic ones, and (ii) their absence in mam-
mals. Thus, these glycofuranosyl conjugates, as well as
their analogues or derivatives, are promising candidates
for new drugs.2 The detailed mechanisms of their bio-
synthesis and their metabolism have not yet been com-
pletely elucidated. In addition to classical hydrolases3
and transferases,4,5 the involvement of mutases6,7 which
catalyze the interconversion between nucleotide pyran-
osyl and furanosyl sugars has been described. However,
to our knowledge, few of these enzymes have been iso-
lated and studied, except those related to the galactofur-
anosyl framework. For instance, there is no description
in the literature of a gluco-, manno-, fucofuranosidase
or transferase or mutase, even if related hexofuranosides
have already been discovered in natural sources.
From a chemical point of view, hexoses exhibit signif-
icant diﬀerences depending on whether they are present
as pyranosides or as furanosides. Indeed, it is well
known that hexopyranosides are thermodynamically
more favoured than their furanoside counterparts, nota-
bly because steric interactions are minimized in six-
membered rings.8 Moreover, stereoelectronic eﬀects
tend to stabilize electron-withdrawing aglycons with an
axial orientation (Fig. 1). It results from this important
parameter that a-D-pyranosides having a 4C1 conforma-
tion are generally more stable than the corresponding
equatorial b-anomers. Considering now the ﬂexibility
of furanosides, anomeric eﬀects are not able to favour
a- more than b-hexofuranosides since expression ofO
O
O
E11E
ano α-D-furanoβ-D-furano
formations stabilized by anomeric eﬀects.these electronic eﬀects is possible in both cases. Conse-
quently, orbital overlapping in furanosides cannot be
as eﬃcient as in pyranosides and could not explain alone
the greater stability of one furanoside over its anomeric
counterpart. Nevertheless, it was established from stud-
ies of nucleosides that equilibrium between north-type
and south-type conformations is tightly dependent on
anomeric and/or gauche eﬀects involving O-2 or O-3.9–11
Furthermore, an apparent conformation of furano-
sides is mainly an average of all conformations encoun-
tered on a pseudo-rotational way generally involving
envelope to twist interconversions.2,12–15 Finally, this
could explain why protecting group manipulations in
hexofuranosides seem to be slightly restricted in com-
parison with strategies frequently used with pyranosides
(regioselective acylations and etheriﬁcation, selective
opening of benzylidene groups, etc.).
From these general considerations, the purpose of
this review is not to be exhaustive but more particu-
larly to focus on (i) the main biological sources of hexo-
furanosides and their structures, (ii) some recent
advances in the ﬁeld of their chemical and/or chemo-
enzymatic synthesis and (iii) their potential use in vari-
ous domains such as in biology, chemistry and
physicochemistry.2. Structure of natural hexofuranosyl conjugates
Polysaccharides composed of hexofuranosyl residues are
important constituents of glycoconjugates from many
bacteria,16,17 protozoa,18 fungi,19 plants20 and archae-
bacteria.21 Hexofuranosyl constituents have also been
identiﬁed in glycopeptides, glycolipids as well as nucleo-
tide sugars. The structure of the latters will be presented
in the enzymatic synthesis part of this review.
D-Galactose is by far the most widespread hexose in
the furanose form in naturally occurring polysaccha-
rides, and the most impressive examples of these glycans
are encountered in mycobacteria. Moreover, glycocon-
jugate structures including the D-Galf unit in the 1,2-
trans anomeric conﬁguration have been found in many
microorganisms, not necessarily pathogenic, as well as
in some pluricellular organisms. A few of them are O-
glycosidically-linked to another D-Galf unit by (1?2),
(1?3), (1?5) or (1?6) linkages, and others are at-
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Glcp, D-GlcpNAc, D-Galp, D-GalpNAc, D-Frup and
L-Rhap. Some examples are presented in Table 1, withTable 1. Natural b-D-Galf-containing oligosaccharidic structures
Glycosidic linkage Organism(s)a
(1?2)-D-Galf Penicillium22
Talaromyces23,24
Trypanosoma cruzi25
(1?3)-D-Galf Aspergillus24,31
Chaetosartorya24
Penicillium22
Renibacterium
salmoninarum32
Talaromyces23,24
(1?5)-D-Galf Actinobacillus
pleuropneumoniae36
Arachniotus24
Aspergillus24,33,37–40
Bionectria24
Byssochlamys24,26
Chaetosartorya24
Cryphonectria
parasitica27
Discula30
Eupenicillium24,41
Gymanascella
Hypocrea24,28
Mycobacterium16,42–45
Nectria46
Neosatorya24,39
Paecilomyces26
Penicillium22,47
Rocella decipiens
Sesquicillium46
Talaromyces23,24,48
Trichoderma28
(1?6)-D-Galf Arachniotus24
Aspergillus30,39
Bionectria24
Byssochlamys24,26
Calonectria24,62
Cryphonectria
parasitica27
Cyclindocladium62
Discula30
Fusarium63,64
Gibberella24,64
Gymanascella
Hypocrea24,28
Mycobacterium16,42–45
Myrothecium65
Nectria64
Neosatorya24,39
Paecilomyces26
Penicillium22,47
Renibacterium
salmoninarum66
Sesquicillium46
Talaromyces23,24,67
Trichoderma28
aMicroorganisms, whose pathogenicity has been clearly demonstrated, are lindication of the microorganism in which these glyco-
conjugates are present. Importantly, Galf has been
shown to be present in numerous structures consideredGlycosidic linkage Organism(s)
(1?2)-D-Manp Bionectria24
Byssochlamys24,26
Cryphonectria parasitica27
Hypocrea24,28
Neurospora24,29,30
Paecilomyces26
Trichoderma28
(1?3)-D-Manp Aspergillus33
Trypanosoma cruzi18,34
Leishmania35
(1?6)-D-Manp Aspergillus33,37,40,49
Epidermophyton30
Microsporum30
Paraccidioides
brasiliensis50
Rocella decipens51
Trichophyton30
(1?3)-D-Glcp Steptococcus thermophilus
Sﬁ3952
(1?6)-D-Glcp Escherichia coli K-1253
(1?4)-D-GlcpNAc Trypanosoma cruzi25
(1?3)-D-Galp Agelas sp.54
Agelas longissima55
Bacteroides cellulovens56
Fibrobacter succinogenes S8557
(1?3)-D-GalpNAc Bacteroides fragilis 934358
Hafnia alvei59
Escherichia coli O16460
Shygella dysenteriae type 360
(1?4)-L-Rhap Mycobacterium16,42–45
Pleisiomonas
shigelloides61
(1?3)-D-Frup Rahnella aquatilis68
O
OH
OH
OH
OR
OH
β-D-Galf-(1→X)
abelled in bold face.
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isms. In addition to Galf, Fruf is one of the most com-
mon furanosidic monosaccharide found in nature but in
less abundant varieties of polysaccharide structures.
Others besides these sugars could be encountered more
scarcely in bacteria or plants, for example, D-Glcf, D-
Fucf or even D-Manf.
2.1. Mycobacteria
One notable example is that of Mycobacterium tubercu-
losis, which despite several decades of successful chemo-
therapeutic treatment has reemerged through multidrug
resistance to become a major cause of mortality, with
an annual rate of approximately 3 millions over the
world.69 The cell wall complex in this species is largely
composed of two polysaccharides, a lipoarabinoman-
nan (LAM) and an arabinogalactan (AG), in which
all the galactose and the arabinose residues are present
as ﬁve-membered rings.16,70 The AG portion of myco-
bacteria comprises a linear chain of approximately 30
alternating b-(1?5)- and b-(1?6)-linked D-Galf resi-
dues (Fig. 2). Each galactan chain is believed to contain
2 or 3 arabinan chains and the linkage position is to O-
5 of the Galf unit. The mycobacterial cell wall core,
consisting of an outer lipid (mycolic acid) layer at-
tached to peptidoglycan via the AG, is unique to myco-
bacteria and other Actinomycetes. Therefore, the
inhibition of the pathways leading to its formation is
particularly attractive from the perspective of drug
development.71 Indeed, inhibition of the enzymes that
assemble these polyfuranosides prevents the prolifera-
tion of mycobacteria, including the causative agent of
tuberculosis, M. tuberculosis.72,73 These ﬁndings, and
the fact that such furanosyl residues are not found in
mammals, support the research on these enzymes as
important targets for the design of new antituberculosis
drugs.O
OH
OH
OH
O
O
OH
OH
O
HO
O
O
OH
OH
OH
O
β-(1→5)
β-(1→6)
Figure 2. Galactan fragment of the arabinogalactan from the myco-
bacterial cell wall.2.2. Protozoa
The D-Galf residues are also present in the b-anomeric
conﬁguration in eukaryotic pathogens such as Trypano-
soma cruzi and Leishmania major. Protozoan parasites
of the genus Leishmania are the causative agents of leish-
maniasis, which infects more than 10 million people
worldwide through the sand-ﬂy mediated transmission.
The surface of the promastigote stage of Leishmania is
coated with a variety of interrelated glycoconjugates
including lipophosphoglycan (LPG), glycoinositol phos-
pholipids (GIPLs), proteophosphoglycan (PPG) and
glycosyl phosphatidylinositol (GPI)-anchored pro-
teins.18,35,74–76 In some species of Leishmania, such as
L. major, as well as in T. cruzi, the core of the abundant
surface LPG is structurally related to that of the smaller
GIPLs in containing Galf residues in a b-Galf-(1?3)-
Manp motif, suggesting a common biosynthetic path-
way. Usually the LPG core hexasaccharide myo-inositol
is substituted with an a-D-glucosyl 1-phosphate as
shown in Figure 3. It is worth mentioning that both gly-
colipid complexes LPG and GIPLs act as virulence fac-
tors involved in the recognition and attachment of host
macrophages as well as in binding to the gut of the insect
responsible for the transmission of Trypanosoma or
Leishmania parasites in mammalian host during the dis-
ease process.75,77–81 Moreover, the presence of Galf
units has been demonstrated in N-glycoproteins of some
species of trypanosomatids such as Endotrypanum
schaudinni, where asparagine-linked oligosaccharides
have two peculiarities, the presence of Galf as well as ri-
bose residues.82
2.3. Fungi
Fungi are other microorganisms recognized as an
increasing cause of infection (aspergilloses, systemic
candidoses) especially in immunodeﬁcient patients and
in those treated with immunorepressive agents. It has
been observed that during the growth of moulds, exo-
polysaccharides (EPS) with immunological properties
are produced. Structural analysis of the EPS from
Aspergillus and Penicillium species indicated the pres-
ence of a major core chain composed of (1?2)- and
(1?6)-linked a-D-mannopyranosides, which contained
side chains of around 4–10 units of (1?5)-linked b-D-
galactofuranoside residues (Fig. 4).19 It is noteworthy
that Galf units were shown to be immunodominant in
the galactomannans produced by Aspergillus fumiga-
tus.49,83–86 More recently, Barreto-Bergter and co-work-
ers31 demonstrated that immunodominant epitopes were
present in the O-linked tetra- and hexasaccharides of the
peptidogalactomannan portion of A. fumigatus mycelial
cell wall and contained a b-Galf-(1?5)-b-Galf terminal
group. Despite being the less abundant carbohydrate
component of the A. fumigatus peptidogalactomannan,
O
OH
HO
O
OH
OH
O
OH
HO
O
OH
O
OH OH
O
O
HO
OHO
O O
O
O
NH2
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HO
HO
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O
O
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H
H
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Figure 3. LPG core hexasaccharide myo-inositol fragment found on the surface of the Leishmania parasite.
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Figure 4. Galactomannan core structure of the EPS produced by Aspergillus and Penicillium species.
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niﬁcant part of its antigenicity. At least, a polysaccha-
ride isolated from another species, Aspergillus
versicolor, appears to have a similar structure, except
for the presence of phosphodiester groups. NMR data
suggested that these groups were mainly present as
bridges between C-1 of a-D-Manp and C-6 of 5-O-
substituted b-D-Galf units.87
More generally, the fungal cell wall is mainly built up
of polysaccharides. Among them, the widely distributed
b-(1?3)-glucan is a cell wall component of most medi-
cally important fungi, including A. fumigatus. However,
there is no doubt that other polysaccharides appearing
in minor amounts could be characteristic of a limitedgroup of fungi.46,47 For instance, a novel galactofuranan
has been puriﬁed from ﬁfteen species of Eupenicillium.48
Moreover, in Talaromyces helicus, a heteropolysaccha-
ride rich in (1?2)- and (1?5)-linked Galf units has been
described.88 In some of these species, the galactofura-
nosidic entity appeared to be the antigenic determi-
nant.89 In a very recent study, the release of both b-
(1?5)-Galf antigens and b-(1?3)-D-glucans has been
studied as in vitro Aspergillus markers for the early diag-
nosis of invasive aspergillosis.90
Another noteworthy example of D-Galf-containing
glycoconjugates found in fungi is a glycosylinositol
phosphorylceramide isolated from Paracoccidioides bra-
siliensis, a mycopathogen endemic to rural areas of
O
HO
HO
OH
O
OH
O
HO
OH
O
O
HO
HO
HO
OH
O P
O
ONa
O ceramide
O
OH
OH
HO
HO
Figure 5. Glycosylinositol phosphorylceramide isolated from Para-
coccidioides brasiliensis.
1902 P. Peltier et al. / Carbohydrate Research 343 (2008) 1897–1923South and Central America. Its structure has been
assigned as a-D-Manp-(1?3)-[b-D-Galf-(1?6)]-a-D-
Manp-(1?2)-myo-inositol-(1-phosphoryl-1) ceramide
(Fig. 5).91 Such compound, based on the glycosylation
of myo-inositol-(1-phosphoryl-1) ceramide, forms a spe-
cial class of glycosphingolipids found in plants, yeasts,
ﬁlamentous fungi and protozoas but so far not in animal
cells as mentioned before. Moreover the immunodomi-
nant character of the Galf residue carried by this cera-
mide antigen could be of valuable interest as
serological and taxonomic marker as well as target for
immunodiagnostic agents. The presence of the a-D-Galf
unit has also been demonstrated recently in the a-D-
Galf-(1?6)-a-D-Manp side chains of P. brasiliensis cell
wall.92 This polysaccharide appeared to be shared by
the members of the Onygenales but is not present in
galactomannans of other fungal genera.O
OH
OH
OH
O
OCOR1
OCOR2
OP
O
O-
O
OH
OP
O-
O
OOH
OH
9
Figure 7. Proposed structure of the poly(glycerophosphate) lipotei-
choic acid from Streptococcus sp. DSM 8747.2.4. Bacteria
Glycoconjugate structures including the D-Galf unit in
the 1,2-trans anomeric conﬁguration have been found
in many other microorganisms, not necessarily patho-
genic, including Gram-negative and more rarely
Gram-positive bacteria.32 Once again, the D-Galf-con-
taining conjugates appeared to be essential for virulence
in many pathogenic organisms. These include the lipo-
polysaccharide (LPS) O-antigens of an increasing num-
ber of Gram-negative bacteria,93–95 such as that of→2)-β-D-Galf-(1→6)-α-D-Glcp-(1→3)-α-L-[2-O-Ac
A
→3)-β-D-Galf-(1→3)-α-D-Galp-(1→3)-[β-D-Galf-(1
B D-galact
Figure 6. Galf-containing glycoconjugate structures of Gram-negative bac
Klebsiella pneumoniae O-antigen repeating unit galactan-I.Escherichia coli K-1253,96 (Fig. 6A) or from the enteroin-
vasive E. coli O16460 as well as the Klebsiella pneumoniae
O-antigen repeating unit galactan-I97 (Fig. 6B). They
also could be found in extracellular or capsular polysac-
charides of a variety of both Gram-negative and Gram-
positive bacteria.98–101
A very recent work reported the structural identiﬁca-
tion of a unique poly(glycerophosphate) lipoteichoic
acid from a Gram-positive bacterium, Streptococcus
sp. closely-related to Streptococcus pneumoniae.102 This
lipoteichoic acid is the ﬁrst example in which a monoh-
exosylglycerol, 3-O-(b-D-Galf)-1,2-di-O-acyl-sn-glycerol,
serves as the glycolipid anchor. Moreover, with an aver-
age of 10 glycerophosphate residues, it is the shortest
known to date (Fig. 7). It is also interesting to note that
the motif b-D-Galf-(1?6)-a-D-Galp has been found in
the EPS of human beneﬁcial bacterial strains such as
Lactobacillus rhamnosus isolated from human intestinal
ﬂora103 or from Steptococcus thermophilus produced in
skimmed milk.104 Nevertheless, little is known about
the role of EPS in the adherence of lactobacilli to epithe-
lial cell surfaces.105
Finally, the structure of a sulfated polysaccharide–
peptidoglycan complex produced by Arthrobacter sp.
was characterized by NMR spectroscopy. This revealed
that the sulfated polysaccharide contains a repeating
unit composed of a trisaccharidic motif [6)-b-D-Galf-
(1?6)-b-D-Galf-(1]n with b-D-Glcp linked to one of the
Galf through a (1?2) linkage.106 The sulfated positions
were identiﬁed at C-3 and C-5 of the b-glucosylated Galf
unit, and at C-2 or C-3 of the other Galf residue (Fig. 8).
This sulfated polysaccharide–peptidoglycan complex]Rhap-(1→3)-α-D-GlcpNAc-(1→
α-D-Glcp
→3)-α-D-Galp]n-(1→3)-β-D-GlcpNAc-lipid A
an I repeating unit
↓
1
6
teria. (A) Escherichia coli K-12 LPS O-antigen repeating unit. (B)
OOR
OR
O
HO
O
OH
OR'
OR'
O
O
R = SO32-
R' = H or SO32-OH
OH
O
HO
OH
Figure 8. Sulfated trisaccharidic repeating unit of the polysaccharide–
peptidoglycan complex produced by Arthrobacter sp.
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to inhibition of angiogenesis.107 Moreover, whereas
galactofuranan polysaccharides from bacterial cell wall
had been reported previously, this one appeared to be
unique due to the presence of sulfate groups.
As far as D-Fruf is concerned, it has been demon-
strated that many bacteria build polyfructosides named
levan consisting in b-(2?6)-linked D-Fruf with a termi-
nal non-reducing D-Glcp unit.108 Little is known about
their function in bacteria. Very recently, cyanobacterial
oligosaccharides a-D-Glcp(1?2)n-b-D-Fruf (n 6 9) were
isolated from Nostoc species.109,110 Their role as natural
thermoprotectants has been suggested.2.5. 1,2-cis Hexofuranosides in bacteria
It should be underlined that the D-Galf unit in the rare
1,2-cis conﬁguration is sometimes present in the previ-
ously mentioned oligosaccharides. This is the case in
some bacterial strains of Clostridium thermocellum,111
which produce a high molecular-mass, cellulose binding,
multicellulase-containing protein complex, termed the
cellulosome. Structural analysis of the latter revealed a
few tetrasaccharidic units incorporating an a-D-Galf
core (Fig. 9). Other a-D-Galf containing polysaccharidic
structures have been identiﬁed in various bacteria112,113O
OH O
HO
O
O
OH
HO
O
OH
OH
O
OH
HO
OH
OH
O
OH
NHAc
HO
OH
Figure 9. a-D-Galf containing fragment of the cellulosome from
Clostridium thermocellum.as well as in other microorganisms such as the fungus
Adopus dedicuus.114
Surprisingly, this 1,2-cis conﬁguration appeared to be
less uncommon considering the occurrence of Fucf con-
taining glycoconjugates. Whereas Fucf naturally exists in
both D- and L-series, derivatives of the latter are rare
even if this enantiomer is the most abundant one. For
example, a C-L-fucofuranosyl compound is produced
by Streptomyces collinus ssp. albescens and by Strepto-
myces gilvotanareus.115–119 This novel C-glycosyl com-
pound, named toromycin or gilvocarcin V, depending
on the producing organism, has revealed antibiotic and
antitumoural activities.117,118 Another antibiotic pro-
duced by Streptomyces hygroscopicus NRRL 2388, and
named hygromycin A, was recently shown to contain a
5-deoxy-a-L-Fucf moiety.120 Moreover, glycoconjugates
including the D-Fucf unit have been identiﬁed in bacteria
and appeared to exist only in the 1,2-cis anomeric conﬁg-
uration (Table 2). For instance, the Gram-positive bacte-
rium Eubacterium saburreum produces antigenic homo-
or heteropolysaccharides containing a linear chain com-
posed of D-glycero-D-galacto-heptose (Hep) as their core
structure, as well as a-D-Fucf residues in some chemo-
types such as E. saburreum T15 and T19.121,122 These
bacterial strains are frequently isolated from human den-
tal plaques, periodontal pockets and infectious dental
pulp. a-D-Fucf components are also found in speciﬁc
structures of the outer membrane polysaccharides of
phytopathogenic species, such as Xanthomonas or Pseu-
domonas syringae and are thought to play a decisive role
in host–parasite interactions.123,124
Finally, the D-Glcf residue has been identiﬁed as a
phosphate-linked nucleotide derivative, agrocine 84,
produced by the Agrobacterium tumefaciens K84 strain.
It has been shown that it acts as a natural antibiotic,
controlling crown gall on stone fruit trees, caused by
the sensitive phytopathogenic strain Agrobacterium
radiobacter (Fig. 10).126–130 Absolute conﬁguration at
the anomeric position has not been determined yet.
2.6. Plants and other eukaryotic organisms
2.6.1. Plants. The presence of diﬀerent hexofurano-
sides has been demonstrated in natural structures of
plants. For instance, a new purine derivative including
a D-Glcf unit and presenting cytokinin activity was iso-
lated from the fruits of Zantedeschia aethiopica
(Fig. 11A).131 As far as the D-Glcf unit is considered,
this is the ﬁrst natural C-glucofuranosyl chromone re-
ported. It was isolated from the leaves of Aloe barbaden-
sis132 and named neoaloesin A (Fig. 11B). Moreover, the
prymnesin-1 toxin (Fig. 11C), isolated from the red tide
alga Prymnesium parvum, was shown to contain three b-
D-Galf residues as glycosidic units of the C90 un-
branched carbon chain. This unique molecule possesses
rare structural features including four 1,6-dioxadecalin
Table 2. Natural a-D-Fucf containing glycoconjugates
O
OH
CH3
OH
OH
OR
α-D-Fucf-(1→X)
Glycoside Substitution Organism(s) Ref.
O
OH
O
OR2
OR1
OR3
OH
β-D-Hepp
R1 = (1?6)-b-D-Hepp Eubacterium sabbureum T15 121
R2 = (1?2)-b-L-Xulf
R3 = b-D-Hepp-(1?6)
R1 = (1?3)-b-D-Hepp Eubacterium sabbureum T19 122
R2 = H
R3 =Me
O
OH
CH3
OH
O
OR1
α-D-Fucf
R1 = (1?4)-b-D-Hepp Eubacterium sabbureum T19 122
OO
R2O
OH
OR1
H3C
α-D-Rhap
R1 = (1?3)-a-D-Rhap Xantomonas campestris pv. phaseoli var. fuscans GSPB 271 123
R2 = a-D-Rhap-(1?3) Xantomonas campestris pv. malvacearum GSPB 1386 and GSPB 2388 123
R1 = (1?2)-a-D-Rhap Pseudomonas syringae pv. 124
R2 = a-D-Rhap-(1?3) phaseolicola
β-L-Araf
O
OH
OH
O
OR1
R1 = (1?2)-b-D-6d-altHepf Campylobacter jejuni 176.83 (serotype O:41) 125
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O
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Figure 10. D-Glcf phosphate-linked nucleotide derivative produced by
the K84 Agrobacterium tumefaciens, agrocine 84.
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chlorine atoms and reveals potent ichthyotoxic and hae-
molytic properties.133
Besides the common a- and b-glucans, the branched
galactomannans previously isolated from lichens con-
tain b-D-Galp, a-D-Manp or D-Glcp but rarely b-D-Galf.Unusual galactomannan structures have been recently
isolated from the lichen Roccella decipiens.51 Here, two
galactomannan fractions appeared to be substituted by
a b-D-Galf unit at the non-reducing end, at O-5 and/
or O-6 position. In the same way, the presence of a fun-
gus-type b-galactofuranan was unexpectedly demon-
strated in the cultivated Trebouxia photobiont
(cyanobacterial strain) of Ramalina gracilis51 and in
the Scytonema sp. photobiont of the lichen Dictyomema
galbratum.134 Moreover, a D-Manf residue has been
identiﬁed in a unique glycoconjugate isolated from an-
other lichen species Evernia prunastri.135
With regard to Fruf, only the D-enantiomer has been
reported in nature and it is generally found in the b-con-
ﬁguration, although glycans with a-Fruf residues are
known from Zymomonas mobilis and Yersinia interme-
dia.136,137 The most abundant fructofuranoside is obvi-
ously sucrose [b-D-Fruf-(2?1)-a-D-Glcp, Fig. 12 A1]
isolated from sugar beet and sugar cane. However,
bacteria produce polysaccharides that contain b-fructo-
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Figure 11. (A) The D-Glcf-containing purine derivative isolated from the fruits of Zantedeschia aethiopica. (B) The C-Glcf derivative from Aloe
barbadensis, Neoaloesin A. (C) Structure of prymnesin-1-toxin.
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Figure 12. The three trisaccharidic biosynthetic precursors of fructosans produced by plants: (A1) sucrose (B1) b-(2?6)-linked Fruf residue found in
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Figure 13. The glycosphingolipid produced by Agelas sp.,
agelagalastatin.
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produce polyfructofuranosides including inulin-type
and levan-type structures, which are composed of b-
(2?1)- or b-(2?6)-linked Fruf residues, respectively
(B1, B2, C1, C2).20 Highly branched structures compris-
ing both (2?1)- and (2?6)-linked b-fructofuranosyl
units have also been encountered in Gramineae.138 Be-
sides starch, fructans are the most widespread reserve
polysaccharides in higher plants. Moreover, they can
reach the size of 106 Dalton and have been implicated
in drought and frost tolerance.139 Three types of fructo-
sans have been characterized and their structures are de-
rived from three trisaccharidic biosynthetic precursors.
Neokestose (A2) has been isolated from the storage tis-
sues of onion (Allium cepa) and from the roots of Aspar-
agus oﬃcinalis. 6-Kestose [b-D-Fruf-(2?6)-b-D-Fruf-
(2?1)-a-D-Glcp, B2] from the levan-type group has
been found for instance in the leaves of some Gramineae
such as barley (Hordeum vulgare) or in wheat (Triticum
aestivum). 1-Kestose [b-D-Fruf-(2?1)-b-D-Fruf-(2?1)-
a-D-Glcp, C2] is the biosynthetic precursor of inulin in
many plants from the Asteraceae family such as chicory
(Cichorium intybus L.) or Jerusalem artichoke (Helian-
thus tuberosus L.). Kestoses are of interest because of
three main attributes: (i) their sweetness, (ii) the fact that
they are hardly hydrolyzed by digestive enzymes and (iii)
they are preferentially consumed by beneﬁcial bacteria
in the human colon. They are thus used in food as
non-caloric and non-cariogenic sweeteners as well as
biﬁdus-growth factor and prebiotic nutriments.140–142
They are industrially prepared by the partial hydrolysis
of inulin extracted from chicory or by enzymatic synthe-
sis from sucrose.143 In addition, alkyl D-fructosides as
well as oligosaccharides incorporating the b-D-Fruf unit,
generally uncommon in plants, have been isolated very
recently from diverse plant species: Saussurea lappa,144
Vigna mungo L.,145 A. oﬃcinalis,146 the fruits ofMorinda
citrifolia.1472.6.2. Marine sponges. The a-D-Galf unit linked to a b-
D-Galf unit has been identiﬁed in a glycosphingolipid
produced by the marine sponge Agelas sp.54 This mole-
cule, termed agelagalastatin (Fig. 13) displays antitu-
moural activity against certain human cancer cell lines.OH
O
OH
AcHN
COOH
O O
HO OH
OH
HO
O
O
OOH
OH
O OH
OH
OH
CH3
Figure 14. L-Fucf-containing acanthaganglioside AG1 of the starﬁsh AcanthThis furanosyl-ceramide constitutes one of the very rare
natural galactofuranosyl-ceramides, which are known as
characteristic membrane components of eukaryotic
cells. Indeed, these natural glycosphingolipids so far iso-
lated from marine sponges share the same core struc-
ture: a ceramide directly glycosylated with a D-Galf
unit or with a D-Galf-(1?3)-D-Galp disaccharidic
unit.55,148
2.6.3. Starﬁsh. Three gangliosides were obtained from
the whole body of starﬁsh Acanthaster planci and named
acanthagangliosides AG-1, AG-2 and AG-3.149,150 The
structure of the oligosaccharide moiety was determined
by NMR spectroscopy and appeared to diﬀer from the
terminal monosaccharide moiety. The non-reducing b-
D-Galf in AG-2 and AG-3 is linked to C-3 of an a-D-
Galp entity whereas the terminal b-L-Fucf (Fig. 14) in
AG-1 is linked to C-4 of an a-D-Galp unit. The ganglio-
sides of A. planci have a terminal characteristic furanose-
type sugar unit, an oligosaccharidic structure only found
in starﬁsh belonging to the order of Spinulosa.
2.6.4. Archaebacteria. In archaebacteria, the tetraether
bipolar lipids are thought to form monolayers, allowing
the microorganisms to maintain membrane integrity in
harsh environments (hot springs, sub-marine volcanic
ﬁelds, Antarctic ice-ﬁelds, etc.).21 The presence of b-D-
Galf units in these lipids is noteworthy. Even if these
moieties are supposed to stabilize the membrane struc-
ture by interglycosyl headgroup hydrogen-bonding, the
occurrence of the furanosyl sugar in extreme environ-OHO
OO
OH
NH
(CH2)11CH3
OH
OH
O (CH2)22CH3
OH
O
O
H H
aster planci.
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ing point. Indeed, the furanosides are known to be much
more rapidly hydrolyzed than their pyranosyl
counterparts.1513. Recent advances in the synthesis of hexofuranosyl-
containing oligosaccharides and conjugates
Most of the time, required furanosyl intermediates are
more easily available in signiﬁcant yields starting from
pentoses than from hexoses. Indeed, both acid-catalyzed
Fischer glycosidation of reducing hexoses and their di-
rect acylation under standard conditions aﬀord hexofur-
anosyl derivatives and hexopyranosyl compounds,
respectively. Consequently, the synthesis of hexofura-
nose-containing glycosides and conjugates involves
methodologies speciﬁcally dedicated to hexoses. Some
important results were obtained for D-Gal, for which
perbenzoylation had to be carefully controlled at high
temperature to give the desired furanose,152 and for D-
Glc whose peracetylation was performed in the presence
of boric acid.153 An alternative and more general ap-
proach proposed ﬁrst to lock the hexofuranosyl ring
by Fischer glycosylation of long chain alcohols. This
reaction was promoted by ferric chloride in the presence
of additional salts, such as calcium or barium chlo-
ride.154–156 The alkyl chain acts here as a temporary pro-
tection of the anomeric centre, thus preventing any ring
expansion. Protecting group manipulation and activa-
tion reactions further yielded a large panel of furanosyl
synthons, even the key peracylfuranoses.157 A direct
synthesis of alkyl hexosides was also developed starting
from free hexoses but using an electrophilic reagent, a
strong base, and N,N0-dimethylpropyleneurea (DMPU)
as a solvent.158 Up to now, only alkyl a-D-galactofur-
anosides were eﬃciently obtained under such condi-
tions. With regard to the last example, the aliphatic
chain was also interestingly replaced by a pentenyl one
so that the preparation of n-pentenyl hexofuranosides
was performed in only one step.159
On the basis of these general considerations, the
chemical synthesis of a fragment of natural hexofura-
nose-containing saccharides was described.2,12 Assum-
ing that D-Gal is the most widespread hexose in such
compounds, much eﬀort was dedicated to its chemistry.
Approximately all of the most known families of donors
were used to prepare di- and trisaccharides: furanosyl
halides,160 in spite of their low stability, 1-acyl do-
nors,161–163 even if they are a priori less reactive than
other donors, n-pentenyl furanosides,159,164 trichloro-
acetimidates,163,165–167 thiofuranosides,157,163 sulfox-
ides168,169 and also recently thioimidates.163,170–173
Related studies eﬃciently aﬀorded disaccharidic se-
quences such as b-D-Galf-(1?5)-b-D-Galf and b-D-
Galf-(1?6)-b-D-Galf,163,166,174–176 b-D-Galf-(1?6)-Manp176 and b-D-Galf-(1?4)-GlcpNAc.167 More chal-
lenging tasks deal with the synthesis of higher oligosac-
charides characterized by the presence of internal
galactofuranosyl entities. This required a regioselective
glycosylation of a furanosyl acceptor and the activation
of the furanosyl anomeric centre, or vice versa. While
standard approaches were nicely carried out for the syn-
thesis of hexagalactosides,165 de Lederkremer and co-
workers interestingly proposed suitably protected deriv-
atives of D-galactono-(1?4)-lactone as key precursors
so that they were able to synthesize trisaccharidic units
of the galactan produced by M. tuberculosis177 and
Leishmania species178 (Scheme 1).
On another hand, Ning andWang synthesized a galac-
tofuranose disubstituted in positions 5 and 6 by an ara-
binofuranosyl unit and a galactosyl one, respectively
(Scheme 2).179 This one-pot preparation relied on the
galactosylation of 3-O-benzoyl-1,2-O-isopropylidene-D-
galactofuranose at the primary position followed by 5-
O-arabinofuranosylation of the resulting disaccharide.
Final deprotection allowed the authors to obtain a
reducing Galf since position 5 was no more reactive for
cyclization. The key monoacetonide template was also
used for the ﬁrst synthesis of the trisaccharide repeating
unit of the cell wall galactans of Biﬁdobacterium catenul-
atum and its hexasaccharidic dimer.166
Much more complex natural galactofuranose-contain-
ing oligosaccharides were also prepared according to
multi-step syntheses. The ﬁrst examples described in
2000 dealt with a subtle approach to hexa- and hepta-
saccharidyl myo-inositols found in the lipophospho-
glycans of Leishmania parasites.162 The key steps of
this synthesis were the use of (i) a small number of
orthogonal protecting groups and glycosyl donors, and
(ii) a tetraacetyl galactofuranose derivative having a
free hydroxyl function at position 3. The latter com-
pound was ﬁrst glycosylated and subsequently engaged
without any further activation in coupling with an ino-
sitol-containing acceptor (Fig. 15). More recently, per-
acetylated Galf was also proposed as an eﬃcient
furanosyl donor for the outstanding synthesis of the
pseudo-octasaccharidic part of the lipopeptidophospho-
glycan produced by the infectious agent T. cruzi.161
These molecules are characterized by hexofuranosyl res-
idues with a 1,2-trans anomeric stereochemistry that was
obtained via the anchimeric assistance of a 2-O-acyl
group.
As for their pyranosyl counterparts, the synthesis of
1,2-cis hexofuranosides presents increased diﬃculty not
only due to the relative cis orientation between the agly-
con and the group at position 2, but also because hin-
drance eﬀects compete with anomeric ones.
Nevertheless, during the last ﬁve years, important
improvements were made for the stereocontrolled syn-
thesis of 1,2-cis hexofuranosides. O-Glycosylation spe-
ciﬁcally leading to a-D-galactofuranosides was ﬁrst
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Scheme 1. Strategy relying on the use of galactonolactone for the synthesis of a galactofuranosyl containing trisaccharide.
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tain pure alkyl derivatives starting from D-Gal and elec-
trophilic reagents and using DMPU as a solvent.158 Thisapproach was further applied to the synthesis of the cor-
responding n-pentenyl donor, which oﬀered the oppor-
tunity to nicely introduce an acyl protecting group
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Figure 15. Retrosynthetic scheme for the preparation of the inositolphosphoglycan fragment produced by the Leishmania parasite.
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Scheme 3. Synthesis of the a-D-Fucf-(1?4)-b-D-Galp disaccharide.
P. Peltier et al. / Carbohydrate Research 343 (2008) 1897–1923 1909selectively at position 2.180 The resulting galactosyl do-
nor was then converted into a fucofuranosyl donor bear-
ing a 4-methoxybenzyl group at O-2. The latter wasrequired for tethering a galactopyranosyl entity allowing
its intramolecular transfer (Scheme 3) to yield the ﬁrst a-
D-Fucf-(1?4)-b-D-Galp disaccharide.
1910 P. Peltier et al. / Carbohydrate Research 343 (2008) 1897–1923Instead of the PMB intermediate, Fairbanks and col-
leagues favoured the allyl protecting group to mediate
intramolecular aglycon delivery to perform the synthesis
of three disaccharides containing a non-reducing a-D-
glucofuranosyl entity (Fig. 16).181
Very recently, Lowary’s team developed an alterna-
tive approach involving the stereocontrolled openingOBn
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Figure 16. a-D-Glucofuranosyl-containing disaccharides.
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authors nicely extended their approach to the synthesis
of the pentasaccharidic fragment of varianose, a cell
wall component produced by Penicillium varians which
is structurally characterized by the presence of galacto-
furanosyl units (i) substituted at O-2, O-5 or O-6, and
(ii) having either the a- or b-conﬁguration.175
A most impressive achievement with the preparation
of hexofuranosides is related to the total synthesis of
marine agelagalastatin (Fig. 13), a glycosyl ceramide
whose trisacharidic part is built up with one a- and
one b-galactofuranosyl entity. The 1,2-cis furanosyla-
tion was carried out from a 20-carboxybenzyl galactoside
as a donor, which had non-participating protecting
groups and which was activated by triﬂic anhydride in
the presence of DTBMP. On the other hand, the ﬁrst
1,2-trans coupling was orthogonally achieved using a
similar donor, but notably protected with a 2-O-acyl
group, and using a 20-(benzyloxycarbonyl)benzyl galac-
topyranosyl derivative as an acceptor. The resulting tri-
saccharide was further converted into a glycosyl ﬂuoride
to ensure the transfer on a ceramide chain to aﬀord the
target agelagalastatin in a yield up to 10% for 22 steps
starting from peracetylated galactofuranose.183
Amongst other complex compounds of biological sig-
niﬁcance, uridine 50-diphospho (UDP)-furanoses are
more particularly important since they are key sub-
strates to investigate the process involved in the hexof-
uranose incorporation within cell wall glycoconjugates,
and therefore to study two families of enzymes, that is,
UDP-pyranose mutases and hexofuranosyltransferases.
Up to now, UDP-a-D-Galf is the only natural substrate
identiﬁed to naturally transfer hexofuranosyl entities.
This is the reason why many eﬀorts were dedicated to
its synthesis. While enzymatic methods had been pro-
posed earlier,184 even for ﬂuorinated analogues,185 sub-
stantial amounts of UDP-a-D-Galf were ﬁrst obtained
in 2000 independently by Tsvetkov and Nikolaev,186
and Zhang and Liu187 via chemical methods. The latter
relied on the coupling between a-D-galactofuranosylN P O
O
OH
O
OCOCF3F3COCO
N
NH
O
O
+
O
O
OH
OH
OH P
O
O
OOH
N
Me
Scheme 5. Synthesis of UDP-a-D-Galf according to Kiessling and co-workephosphate188 and uridine 50-morpholidate. Interestingly,
this synthesis was further optimized by Kiessling and co-
workers who proposed to use a 50-N-methyl phosphory-
limidazolide nucleoside activated at OH-2 and OH-3 by
two triﬂuoroacetyl groups (Scheme 5).189 It is ﬁnally
noteworthy that the labelled UDP-a-D-[6-3H]Galf was
also synthesized.190
An alternative chemical approach was recently devel-
oped by our team involving direct coupling between an
unprotected thioimidate and a phosphoric acid. This
methodology was ﬁrst validated with dry phosphoric
acid and subsequently extended using the acidic form
of UDP (Scheme 6).191,192
While chemical syntheses of hexofuranosyl conjugates
tend to be more and more eﬃcient, the number of meth-
ods involving biocatalysts is still quite limited, probably
due to the low availability of speciﬁc enzymes. Neverthe-
less, Field and colleagues were able to enzymatically pre-
pare UDP-a-D-Galf using a multi-enzyme system
containing non-furanosyl speciﬁc catalysts.193 Concom-
itantly, progress was also made for the preparation of O-
hexofuranosides on the basis of chemo-enzymatic ap-
proaches. An interesting possibility relies on the use of
an a-L-arabinofuranosidase. The wild type AbfD3 was
indeed eﬃcient enough to recognize and transfer 4-nitro-
phenyl galactofuranoside (pNP-Galf) to either pyran-
osyl acceptors in transglycosylation reactions or to
pNP-Galf itself in self-condensation dimerizations
(Scheme 7).194 The versatility of this enzyme was further
demonstrated for the preparation of difucofuranosides
and ﬂuorinated derivatives.195 Recently, the sialylation
of galactofuranose-containing oligosaccharides was car-
ried out with a recombinant trans-sialidase to study the
impact of the presence of furanosyl entities on the trans-
fer of sialic acid galactopyranosyl residues.196 A good
way to improve yields consists in mutating wild type en-
zymes to minimize their hydrolytic ability.197 Unfortu-
nately, unprotected furanosyl donors such as ﬂuorides
are not suitable substrates because of their instability.
Consequently, a ﬁeld of investigation is now opened toO
O
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OH
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O
O P O
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O
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N
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O
O OOH
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Scheme 6. Synthesis of a panel of furanosyl 1-phosphates and UDP-furanoses starting from thioimidates.
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furanosides.
Finally, the use of more speciﬁc furanosyltransferas-
es was also investigated. In 2001, it had been shown
that a single enzyme is able to transfer galactofurano-
syl residues from UDP-a-D-Galf to two disaccharidic
glycolipid acceptors diﬀering in the branching between
both galactosyl moieties.198 This study was recently com-
pleted by Lowary and co-workers who showed that tri-
saccharides are better substrates than disaccharides,
even for the synthesis of oligogalactans presenting alter-
nating b-(1?6)- and b-(1?5) linkages (Scheme 8).44. Hexofuranosides and novel applications
As discussed previously, hexofuranosides are widely dis-
tributed in nature, but essentially in pathogenic organ-isms. Moreover their absence in mammal
glycoconjugates suggests that the enzymes involved in
the metabolism of such sugars in bacteria, fungi and
protozoa would constitute a good target for the design
of new drugs. Therefore they have raised the interest
of glycoscientists due to their potential biological appli-
cations. Besides that particularity, this family of carbo-
hydrates can also be used (like their pyranose
counterpart) as regular polyols, with a high potency of
hydrogen-bonding and an important stereodiversity.
Applications can then be found in the domain of phys-
icochemistry or in chemistry.
4.1. Biological application
The most important applications of hexofuranosides
rely on the biological ﬁeld. They proved to be tremen-
dous tools for the study of the UDP-Galp mutase and
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Scheme 8. Chemo-enzymatic syntheses using of oligogalactans using furanosyl transferases.
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agents. An interesting application has even been de-
scribed for the induction of erythroid diﬀerentiation of
human K562 cells using some esters of glucofuranosides
and mannofuranosides.199,200
4.1.1. Inhibitors of mutase. Up to now, the most studied
enzyme involved in the biosynthesis of hexofuranosides
is certainly UDP-Galp mutase which catalyses the isom-
erization of UDP-Galp to UDP-Galf. However the de-
tailed mechanism of this ﬂavoenzyme is not yet fully
elucidated, although the three-dimensional structure of
the protein has been determined by X-ray.186,201 The de-
sign of analogues is still of tremendous interest, and will
lead to a better understanding of this unique process
while helping in the development of new therapeuticstrategies against tuberculosis, leprosy and other diseases
notably caused by mycobacterial infections. These com-
pounds can be divided into two families: one where the
furanose entity is conserved and the second one where
the oxygen of the ﬁve-membered ring has been replaced
by another element (N, S, Se).
The major drawback of UDP-Galf is its very low sta-
bility in solution, which has raised the diﬃculty of its
synthesis, and has slowed down the progress in the study
of the mutase.186 To avoid this problem, Sinay¨ and col-
leagues have achieved the preparation of the C-analogue
of UDP-Galf (Fig. 17), obtained in 80% yield from the
corresponding phosphonate and an activated UMP.202
This molecule represents the ﬁrst example of a synthetic
inhibitor of UDP-Galp mutase. It is thus of potential
interest as antimycobacterial agent, as active molecule
OOH
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P O P O O
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Figure 17. C-Analogue of UDP-Galf.
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Figure 20. Imino-sugars analogues of UDP-Galf.
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logue for UDP-galactopyranose mutase crystallization
studies.
A couple of years later, Zhang and Liu have prepared
the C-2 and C-3 ﬂuorinated derivatives (Fig. 18) and
used them as probes in order to gain insights into the
catalytic mechanism.203 Especially the 3-F analogue rep-
resents an eﬀective inhibitor and the inactivation of the
enzyme can be irreversible under non-reducing condi-
tions. This study strongly suggests the involvement of
a covalent intermediate formed between the sugar and
a catalytic nucleophile such as the ﬂavine cofactor itself.
Recently, a collaboration between Vincent and Sinay¨
groups has lead to the emergence of a new series of
time-dependent inactivators.204,205 These nucleoside-
diphospho-exo-glycals (Fig. 19), ﬂuorinated or not at
the unsaturated exo-position, allowed to clarify the cat-
alytic properties of the mutase and to postulate that the
inactivation mechanism must involve go through a se-
quence of two-electron processes, that is, protonation
of the anomeric position and then nucleophilic addition,
as opposed to a single electron transfer and then a rad-
ical coupling of the nucleophile.
However, partly due to these studies, the presence of
an oxacarbenium ion like intermediate in the transitionO
OH
OH
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Figure 18. Fluorinated analogues of UDP-Galf.
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Figure 19. exo-glycal analogues and ﬂuorinated exo-glycals analogues of UDstate of the isomerization process is widely admitted.206
Thus, oxonium mimics, like in the strategies thought for
glycosidases and glycosyltransferases inhibition, have
also been considered for the inhibition of the mutase.
So, polyhydroxylated piperidine and pyrrolidine, also
often called azasugars, provide a powerful set of inhibi-
tors of glycosyltransferases as well as glycosidases.
Hence, Lee et al. have synthesized the two pyrrolidine
analogues of Galf shown in Figure 20.207 Even if the
yields were moderate, both compounds inhibited the
mutase as well as the in vitro biosynthesis of the myco-
bacterial galactan at a concentration of 200 lg/mL.
Interestingly, their activity was speciﬁc to that particular
enzyme, since negligible eﬀects were observed on galac-
tosidase. The synthesis of 1,4-dideoxy-1,4-imino-D-
galactitol was further improved to an overall yield of
42% using a ﬁve-step approach from D-glucose.208
Starting from that promising result, Pinto and co-
workers argues that the protonation of the nitrogen
atom in the active site provides electrostatic stabilization
with carboxylate residues. They reasoned that (i) the
permanent positive charge on the sulfonium or the sele-
nium ions would serve to mimic this interaction, and (ii)
an erythritol side chain containing an internal sulfate
counterion would be advantageous in stabilizing the
compound, as in the case of the biologically importantO
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Figure 21. Ammonium, sulfonium and selenium ions as inhibitors of
UDP-Galf.
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Figure 23. Inhibitors of exo-b-D-galactofuranosidase from Penicillium
fellutanum.
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ammonium, sulfonium and selenium salts analogs of
galactofuranose (Fig. 21).211,212 Unfortunately all of
them proved to be very poor inhibitors of the mutase
since concentrations of at least 10 mM were required.
An explanation for this failure, as proposed by the
authors, relies on the presence of a tryptophan residue
located in the putative active site cleft that could interact
with UDP. Since these compounds were lacking that
part, a promising way to enhance such structures will
be to add nucleotide moieties. A similar strategy was re-
cently reported by Liautard et al. resulting in C-imino-
sugar analogues (Fig. 22) via the 1,3-dipolar
cycloaddition of a uridine derivative carrying an allyl-
phosphono group and a galactofuranose-derived cyclic
nitrone.213,214 These novel potential sugar nucleotide
mimics are actually under biological investigation.O
OH
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OH
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S
N
O
OH
OH
OH
S
S
N
OH
Figure 24. Inhibitors of the a-L-arabinofuranosidase AbfD3 from
Thermobacillus xylanyliticus.4.1.2. Inhibitors of hydrolases. Thioglycosides are gen-
erally resistant to acidic and enzymatic hydrolysis. Their
structure closely resembles that of the natural substrate.
Therefore they represent a particular class of inhibitors
of glycosidase and they have often been used for X-
ray investigation of the structure of the enzyme-sub-
strate complex. In addition, they can also be used as gly-
cosyl donors in the convergent synthesis of
oligosaccharides (see above).
De Lederkremmer and Marino applied this concept in
order to inhibit galactofuranosidases, an important tar-
get for the discovery of new drugs.215,216 The thiogalac-
tofuranosides (Fig. 23) were easily obtained in good
yields (generally higher than 85%) by S-glycosylation
of penta-O-benzoyl-galactofuranose in the presence ofN+
OH
OH
OH
P O O
OH OH
N
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O
O
O
OH
H O BBr-
OH
Figure 22. Imino-sugars as new mimics of UDP-Galf.SnCl4 or BF3. Et2O as catalyst, followed by O-deacety-
lation with sodium methoxide. The compounds demon-
strated moderate to good IC50 values up to 80 lM.
Moreover, de Lederkremer and Alves have extended
the biological application’s ﬁeld of such inhibitors and
cleverly immobilized 4-aminophenyl 1-thio-b-D-galacto-
furanoside on CH-Sepharose 4B in order to form a
matrix for aﬃnity puriﬁcation of exo-b-D-galactofura-
nosidase.3 Following that example, we have recently
synthesized a series of thioimidoyl furanosides as inhib-
itors of the a-L-arabinofuranosidase AbfD3.217 This
particular enzyme is able to degrade the biomass and
has also been used as an eﬃcient biocatalyst to prepare
natural and non-natural disaccharides.195,218,246 More-
over, it has been shown recently that the lack of activity
of the a-L-arabinofuranosidase XYL3 resulted in the de-
crease of seed size and a delayed germination without
aﬀecting the seed viability.219 Despite the fact that our
best thiogalactofuranoside derivative proved to be a
very weak inhibitor (Fig. 24), it helped us in designing
the thiazol-2-yl thioarabinofuranoside, which demon-
strated a good inhibition constant of 1.2 lM.N+
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Figure 25. Enzyme inhibitors from fructofuranosides.
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Figure 27. C-Phosphonate analogue of decaprenolphosphoarabinose
as antimycobacterial agents.
OO OO
O H
N
S
(CH2)11 NH
S O
O O
O
O
Figure 28. 2-C-(2,3:5,6-di-O-isopropylidene)-b-D-mannofuranosyl-
dithioacetate derivative.
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hexofuranosyl compounds since it represents the sec-
ond most abundant simple sugar in nature and so is a sig-
niﬁcant component of human dietary sugar intake. Two
recent examples of inhibitors of enzymes of the fructose
metabolism can be found in the literature (Fig. 25). The
ﬁrst one is based on a simple thiofructofuranoside which
proved to be a very eﬃcient inhibitor of b-D-fructofuran-
osidase and also rat intestinal sucrase.220 The second
compound, 6-O-allyl-D-fructose, obtained in more than
20% overall yield from methyl D-fructofuranoside, has
also demonstrated some activity on the mammalian so-
dium independent transporter of D-fructose named
GLUT5, with a Ki of 20.3 mM.
221
4.1.3. Antimycobacterial agents. Key structural com-
ponents of the mycobacterial cell wall are arabinogalac-
tan and lipoarabinomannan. Both are known to be
essential to the viability of the organisms and to be
responsible for impermeability of the cell wall to many
antibacterial drugs. Although considerable eﬀorts have
been made for developing inhibitors targeting this bio-
synthetic pathway, there are few based on the Galf
structure that demonstrated signiﬁcant activity. Promis-
ing leads lie in the N,N-dialkyl sulfenamide and sulfon-
amide derivatives as well as their S–C isosteres recently
described by von Itztein and co-workers (Fig. 26).222,223
All of them showed in vitro inhibition of mycobacterial
growth with MIC below 5 lg/mL.
Apart from that strategy, Centrone and Lowary have
recently reported the synthesis of six C-phosphonate
analogues of decaprenolphosphoarabinofuranose
(Fig. 27) as inhibitors mimicking the donor substrate
of arabinofuranosyltransferases responsible for the bio-
synthesis of such glycopolymers.224 Among them, one
revealed an interesting MIC of 3.13 lg/mL.O
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Figure 26. Examples of galactofuranosyl dialkyl sulfenamide and
sulfonamide as antimycobacterial agents.4.1.4. Cancer therapy. Agelagalastatin (Fig. 13) is a
natural glycosphingolipid isolated from Agelas sp.54
and its total synthesis has been described recently.183 Be-
sides its unique structure, this compound displayed sig-
niﬁcant in vitro inhibitory activities against human
cancer cell growth with GI50 values ranging from
0.77 lg/mL for lung NCI-H460 to 2.8 lg/mL for the
ovarian OVCAR-3. Another interesting example of
hexofuranoside showing antitumour activity on various
cell lines has been published by Dominguez et al.225 This
compound (Fig. 28) is a synthetic C-glycosyl analog of
D-mannose, obtained in 71% yield by the reaction be-
tween a dithioester and 1,12-dodecyldiamine.4.2. Chemistry
In addition to the important biological applications of
such hexofuranoside derivatives, and keeping aside their
utilization as glycosyl donors or chiral pool, they have
also been used in the ﬁeld of chemistry for various appli-
cations. Perhaps the most ingenious one has been devel-
oped by Kobayashi in 1997 known as the
‘‘fucofuranoside method”.226 This technique allowed
the determination of the absolute conﬁguration of sec-
ondary alcohols as well as tertiary ones substituted with
methyl and twomethylene groups,227 simply by derivatiz-
ing them to a 1:1 mixture of b-D- and b-L-fucofuranosidesO
OH
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O
R1
R2 OHO
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*
*
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Figure 29. The fucofuranoside method.
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Figure 31. Examples of chiral hexofuranose-based ligands used in
asymmetric catalysis.
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Following this method, if the secondary alcohol is of
(S)-type, then the diﬀerence between the 13C chemical
shift values of the anomeric carbon, a-carbon and the
left-hand b-carbon is signiﬁcant and negative, but it is
small for the right-hand b-carbon. If the alcohol is of
(R)-type, the diﬀerence follows a similar scheme (invert-
ing the role of the left-hand and the right-hand b-carbon)
but with positive values. This was exempliﬁed during the
determination of the absolute stereochemistry of lupine
triterpenoids36 and completed by the arabinofuranoside
method.228
Inorganic chemistry is another ﬁeld of application for
hexofuranosides. It is noteworthy that pentacoordinate
phosphorus is considered to be an intermediate or tran-
sition state in the formation or in the hydrolysis of bio-
logically relevant phosphorus compounds such as DNA,
RNA and c-AMP. Thus modelling active site interac-
tions of phosphoryl transfer enzymes and obtaining so-
lid-state structural information are of utmost interest.
Holmes group is among the major actors of this domain
and his team has recently prepared and solved the X-ray
structures of several biologically relevant phosphoranes
based on glucofuranose and xylofuranose.229–231 One
example is represented in Figure 30.
Finally, the most promising way of using hexofurano-
sides lies in catalysis.232 Asymmetric catalysis is usually
a strategy where a transition metal complex containing a
chiral ligand catalyses the transformation of a prochiral
substrate into one enantiomer as a major product. From
this simple deﬁnition the design of the chiral ligand ap-
pears to be a crucial step and carbohydrates are a natu-
ral and cheap source of compounds owing with several
stereogenic centres. This major topic has recently been
reviewed by Die´guez et al.232 and, therefore, only two
samples of chiral ligands based on the hexofuranose
framework are shown in Figure 31.4.3. Physicochemical applications
Interest for carbohydrates and their potential appli-
cations in materials has recently raised due to theirOO
O
O
OH
O
PF
Figure 30. Example of a biologically relevant phosphorane.high potency for hydrogen-bondings and because
they are likely to be biocompatible and biodegradable.
Hexofuranosides are in no way excluded from that
research.4.3.1. Amphiphiles and gelators. Lipids of thermophilic
and thermoacidic Archaebacteria are characterized by
tetraether-type macrocylic components bearing one or
two polar headgroups derived from phosphate and/or
sugar moieties (even hexofuranoses) at the terminal
ends of a lipidic backbone.151 These latter ﬁt well in
the class of bolaamphiphiles, which consists in mole-
cules possessing two polar headgroups connected to
each other through one or more hydrophobic spacers.
These macrocyclic molecular components are of utmost
interest as they are able to form advanced liposomes
and artiﬁcial membranes with advantageous properties
like mechanical, chemical and enzymatic stability for
instance. Therefore they represent good candidates
for biotechnological applications such as fertilization,
drug or antigen delivery and membrane proteine/pep-
tide reconstitution. However, obtaining suﬃcient
amounts of chemically pure material from natural
sources still remains diﬃcult. Thus, for more than 10
years now, Benvegnu, Plusquellec and co-workers have
developed the synthesis of symmetrical and unsymmet-
rical analogues of such derivatives (Fig. 32) and stud-
ied their physical properties.233–239 Among them,
some compounds with the capacity to self-assemble
into monolayer systems are currently under investiga-
tion for the encapsulation and the delivery of
biomaterials.
In recent years the development of new gelators of or-
ganic ﬂuids as well as the investigation of gelating pro-
cess and gel structures has received much attention.
The gelators can be classiﬁed into two categories accord-
ing to the diﬀerence in the driving force for the molecu-
lar aggregation: non-hydrogen-bond-based gelators or
hydrogen-bond-based gelators. Saccharides, having free
OH groups, fall within the latter group. Once again, D-
glucofuranose ketal derivatives under diﬀerent monoac-
etal forms (Fig. 33), demonstrated high gelating ability
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Figure 32. Synthetic symmetrical and unsymmetrical analogues of natural archaeal glycolipids.
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Figure 33. D-Glucofuranose structures of some small organic gelators.
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Figure 34. Chemical structure of an eﬃcient hydrogelator based on
azobenzene core and a pentofuranose.
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form, cyclohexane, etc.) at a concentration sometimes
lower than 30 mg/mL.240–242 Interestingly, its C-3 epi-
mer D-allofuranose exhibited very poor ability to form
gels, probably due to a diﬀerent network of hydrogen-
bondings as shown by their crystal structure.
The design of small molecules able to gel water still re-
mains a challenge. They represent attractive targets since
it is sometimes possible to delineate various factors at
the molecular level that are responsible for gelation in
preference to crystallization, solubilization, or precipita-
tion. The tetrameric sugar-based azobenzene (Fig. 34)
showed pronounced gelation ability of water from pH
4 to 10 and even in the presence of diﬀerent salts in aq-
eous media.243 This process notably involved hydrogen-
bondings through sugar moieties and p–p stacking of
the benzene rings. Unfortunately none of the closely-re-
lated hexofuranose analogues synthesized showed
hydrogelation properties.4.3.2. Dendrimers. However, these hexofuranose ana-
logues designed previously have served as scaﬀolds for
a new glycodendrimer (Fig. 35).244 It is noteworthy thatthis new structure bears an azobenzene stem with easy
cis–trans isomerization property which may be useful
for the construction of photoswitchable devices.
4.3.3. New biopolymers. Finally, the preparation of
hyperbranched polysaccharides Poly-1 and Poly-2 has
been achieved by ring-opening multibranching polymer-
ization of 1,6-anhydro-D-glucopyranose and 1,6-anhy-
dro-D-galactopyranose using a thermally induced
cationic initiator (Fig. 36).245 NMR analysis revealed
17 kinds of repeating units for Poly-1 and 23 kinds for
Poly-2, among which an important proportion of hexo-
furanosides has been described. Their structures proved
to be spherical and the low intrinsic viscosity as well as
the lack of entanglement should allow the use of such
polymers as biocompatible and biodegradable viscosity
modiﬁers.
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Figure 35. A glycodendrimer.
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Figure 36. Synthesis of hyperbranched D-glucan and D-galactan.
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